Kolkata, India: Emcure Pharmaceuticals Ltd. and its biotech subsidiary, Gennova Biopharmaceuticals Ltd. have amicably resolved all legal disputes with HDT Bio Corp. The litigation between them, including before US courts and the arbitral tribunal in London, has been settled and dismissed. Gennova and HDT, who previously collaborated on the successful development of Gennova’s mRNA Covid-19 vaccines will once again collaborate on the development and commercialization of mRNA vaccines.
The parties have entered into a long-term agreement to develop mRNA vaccines against a broad range of infectious diseases, in India and several other countries. As part of their agreement, HDT has granted a license to Gennova to use HDT’s patented mRNA vaccine technology in multiple fields.
“EMCURE is delighted that the misunderstanding between us and HDT not only stands resolved but we have widened the scope of our technical collaboration on a long term basis. mRNA platform will be the launching pad for our foray into vaccines for tuberculosis, rabies, dengue and other infectious diseases and our collaboration with HDT will be mutually beneficial,” observed Mr. Satish Mehta, CEO & Managing Director of EMCURE.
CEO of HDT, Dr. Steve Reed, echoed Mr. Mehta’s sentiments and added that “HDT’s proprietary technology, combined with Emcure’s & Gennova’s innovation and manufacturing excellence and established distribution network will bring life-saving vaccines to countless people. We are committed to a successful relationship with Emcure and Gennova.”
Disclaimer:
“Emcure Pharmaceuticals Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offering of its equity shares and has filed a draft red herring prospectus dated December 16, 2023 (DRHP) with the Securities and Exchange Board of India (SEBI). The DRHP is available on the websites of the Company at www.emcure.com, SEBI at www.sebi.gov.in, the book running lead managers, Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited, and JP Morgan India Private Limited at https://investmentbank.kotak.com, www.axiscapital.co.in, www.jefferies.com and www.jpmipl.com, respectively, and the stock exchange(s) at www.nseindia.com and www.bseindia.com, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details refer to the Red Herring Prospectus, including the section titled “Risk Factors” of the Red Herring Prospectus, when available. Potential investors should not rely on the DRHP for making any investment decision.”
About Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Established in 1981, EPL is ranked as the 13th largest pharma company in India in terms of Domestic Sales for MAT September 2023. Emcure is present in 70+ countries globally including Europe and Canada. To know more about Emcure, please visit: https://www.emcure.com/
Also Read | US Couple Achieves Pregnancy in Kolkata Clinic After Multiple Failures in Their Home Country
About Gennova Biopharmaceuticals Ltd.
Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is a biotechnology company dedicated to the research, development, production, and commercialization of biotherapeutics and vaccines to address life-threatening diseases across various indications. To find out more, visit https://gennova.bio
About HDT Bio Corp.
HDT Bio Corp. is a Seattle, USA-based, clinical-stage biopharmaceutical development company. With core technology and expertise in nucleic acid formulation, the company develops products that seek to harness host-directed immune responses. HDT Bio’s work focuses on infectious disease and oncology vaccines and therapeutics through early-stage collaborations with partners worldwide. The company’s vaccine platforms combine formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses. Learn more at https://www.hdt.bio.
